PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$71.8M
(+21%)
Cap. Flow
+$62M
Cap. Flow
% of AUM
15.25%
Top 10 Holdings %
Top 10 Hldgs %
55.4%
Holding
62
New
16
Increased
17
Reduced
12
Closed
17
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$19.9M |
| 2 |
AbCellera Biologics
ABCL
|
+$18.6M |
| 3 |
DexCom
DXCM
|
+$9.09M |
| 4 |
Janux Therapeutics
JANX
|
+$8.92M |
| 5 |
BridgeBio Pharma
BBIO
|
+$7.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kelly Services Class A
KELYA
|
+$10.5M |
| 2 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$8.74M |
| 3 |
Alkermes
ALKS
|
+$6.63M |
| 4 |
OrthoPediatrics
KIDS
|
+$5.76M |
| 5 |
Option Care Health
OPCH
|
+$5.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.39% |
| 2 | Miscellaneous | 2.95% |
| 3 | Industrials | 2.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Inspire Medical Systems
INSP
$1.97B
| – | – |
-14,000
| Closed | -$1.87M | – |
|
|
52
Kelly Services Class A
KELYA
$548M
| – | – |
-492,340
| Closed | -$10.5M | – |
|
|
53
OrthoPediatrics
KIDS
$581M
| – | – |
-200,216
| Closed | -$5.76M | – |
|
54
DELISTED
Kezar Life Sciences
KZR
| – | – |
-5,608
| Closed | -$33.6K | – |
|
55
Medtronic
MDT
$121B
| – | – |
-30,000
| Closed | -$2.36M | – |
|
|
56
Option Care Health
OPCH
$4.66B
| – | – |
-205,000
| Closed | -$5.68M | – |
|
57
Privia Health
PRVA
$2.77B
| – | – |
-96,065
| Closed | -$1.67M | – |
|
58
Relay Therapeutics
RLAY
$3.74B
| – | – |
-385,000
| Closed | -$2.51M | – |
|
59
10x Genomics
TXG
$9.52B
| – | – |
-49,021
| Closed | -$953K | – |
|
60
Universal Health Services
UHS
$11B
| – | – |
-9,373
| Closed | -$1.73M | – |
|
61
LENZ Therapeutics
LENZ
$108M
| – | – |
-59,542
| Closed | -$1.03M | – |
|
62
DELISTED
Paragon 28, Inc.
FNA
| – | – |
-261,400
| Closed | -$1.79M | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2024 Portfolio in Review
As of Q3 2024, Prosight Management held 62 positions worth $406M, up 21% from $335M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Prosight Management deployed $62M of net new capital in Q3 2024, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was McKesson: 35,822 shares worth $17.7M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $8.74M trimmed.
- Prosight Management's largest Q3 2024 buy was McKesson: 35,822 shares worth $17.7M.
- Prosight Management added most to AbCellera Biologics in Q3 2024, an estimated $18.6M increase.
- Prosight Management's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $8.74M.
- Prosight Management fully exited Kelly Services Class A in Q3 2024, selling an estimated $10.5M.
- Prosight Management's ten largest holdings make up 55% of its $406M portfolio in Q3 2024.
- Prosight Management opened 16 new positions and closed 17 in Q3 2024.
- Prosight Management's portfolio value rose 21% quarter-over-quarter to $406M.
Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.